1. Home
  2. SAIA vs RDY Comparison

SAIA vs RDY Comparison

Compare SAIA & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saia Inc.

SAIA

Saia Inc.

HOLD

Current Price

$359.97

Market Cap

11.2B

Sector

Industrials

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$12.15

Market Cap

9.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAIA
RDY
Founded
1924
1984
Country
United States
India
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
9.9B
IPO Year
2002
2001

Fundamental Metrics

Financial Performance
Metric
SAIA
RDY
Price
$359.97
$12.15
Analyst Decision
Buy
Strong Buy
Analyst Count
19
1
Target Price
$391.06
$16.90
AVG Volume (30 Days)
487.9K
3.1M
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
0.52%
EPS Growth
N/A
N/A
EPS
5.37
N/A
Revenue
$3,234,286,000.00
N/A
Revenue This Year
$7.29
$7.72
Revenue Next Year
$9.08
$3.50
P/E Ratio
$69.71
$18.67
Revenue Growth
0.79
N/A
52 Week Low
$249.32
$11.36
52 Week High
$494.71
$15.67

Technical Indicators

Market Signals
Indicator
SAIA
RDY
Relative Strength Index (RSI) 33.15 41.01
Support Level $357.64 $11.36
Resistance Level $376.30 $14.08
Average True Range (ATR) 16.81 0.26
MACD -5.69 0.04
Stochastic Oscillator 20.99 54.39

Price Performance

Historical Comparison
SAIA
RDY

About SAIA Saia Inc.

Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 210 facilities and a fleet of more than 7,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: